Bath & Body Works (NYSE:BBWI – Get Free Report) is expected to post its Q4 2026 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of $1.76 per share and revenue of $2.5942 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.
Bath & Body Works Trading Down 3.3%
NYSE BBWI opened at $22.02 on Tuesday. Bath & Body Works has a 12 month low of $14.27 and a 12 month high of $36.89. The stock has a 50-day simple moving average of $22.19 and a 200 day simple moving average of $23.63. The company has a market capitalization of $4.51 billion, a PE ratio of 6.78, a P/E/G ratio of 1.00 and a beta of 1.54.
Bath & Body Works Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 20th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.6%. Bath & Body Works’s dividend payout ratio is 24.62%.
Wall Street Analyst Weigh In
View Our Latest Research Report on Bath & Body Works
Key Stories Impacting Bath & Body Works
Here are the key news stories impacting Bath & Body Works this week:
- Positive Sentiment: Seasonal product collaboration is drawing shopper interest, which could help near-term revenue and support valuation — a Yahoo Finance piece highlights the PEEPS collaboration as a spring merchandising catalyst. Bath & Body Works (BBWI) Valuation Check As PEEPS Collaboration Draws Spring Shopper Interest
- Neutral Sentiment: Barclays raised its price target from $20 to $21 and kept an “equal weight” rating — a modest signal that the stock is fairly valued by the firm but not a strong buy catalyst. Benzinga – Barclays raises PT
- Neutral Sentiment: Another outlet reports a price-target lift to $23 — analyst PT increases provide some support but are incremental compared with the headline risks. Bath & Body Works (NYSE:BBWI) Price Target Raised to $23.00
- Negative Sentiment: Multiple law firms and filings note a securities class action covering purchases from June 4, 2024 to November 2025 with mid‑March lead‑plaintiff deadlines — increased litigation activity raises potential liability, distraction and downside risk for the stock. Representative notices from Robbins LLP and Levi & Korsinsky are here. Robbins LLP lead plaintiff deadline Levi & Korsinsky class action
- Negative Sentiment: Large institutional selling occurred in Q4 as Cooper Creek liquidated about 5.0M shares (roughly $129M at quarter end) — such stake reductions can add selling pressure and signal concern from an investor that previously held a meaningful position. This $129 Million Bath & Body Works Stake Got Liquidated
Hedge Funds Weigh In On Bath & Body Works
A number of large investors have recently modified their holdings of BBWI. Parallel Advisors LLC raised its holdings in Bath & Body Works by 42.6% during the fourth quarter. Parallel Advisors LLC now owns 1,897 shares of the company’s stock worth $38,000 after acquiring an additional 567 shares in the last quarter. Meeder Asset Management Inc. raised its stake in shares of Bath & Body Works by 28.5% during the 4th quarter. Meeder Asset Management Inc. now owns 2,874 shares of the company’s stock worth $58,000 after purchasing an additional 637 shares in the last quarter. State of Wyoming boosted its holdings in shares of Bath & Body Works by 6.2% in the 2nd quarter. State of Wyoming now owns 11,294 shares of the company’s stock valued at $338,000 after buying an additional 661 shares during the last quarter. Vident Advisory LLC grew its stake in shares of Bath & Body Works by 2.8% in the second quarter. Vident Advisory LLC now owns 25,229 shares of the company’s stock valued at $756,000 after buying an additional 692 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock valued at $35,000 after buying an additional 801 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors and hedge funds.
Bath & Body Works Company Profile
Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.
Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.
Featured Stories
- Five stocks we like better than Bath & Body Works
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.
